{"disease":{"id":"erdheim-chester-disease","name":"Erdheim-Chester Disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"vemurafenib","indication_name":"Erdheim-Chester Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zelboraf","generic_name":"vemurafenib","company_name":"Hoffmann La Roche","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase B-raf","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":"100","mechanism":"Zelboraf blocks the activity of the B-raf protein, which is involved in cell growth and division."},{"drug_id":"zelboraf","indication_name":"Erdheim-Chester Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zelboraf","company_name":"Hoffmann-La Roche","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase, Ferrochelatase, mitochondrial, Dual specificity mitogen-activated protein kinase kinase 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06332183","title":"GWAS and EWAS in Patients With Erdheim-Chester Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Augusto Vaglio","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06317246","title":"Subtypes and Prognostic Factors in Erdheim-Chester Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Meyer Children's Hospital IRCCS","has_results":false},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04198818","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"Haihe Biopharma Co., Ltd.","has_results":true},{"nct_id":"NCT05092815","title":"The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT03794297","title":"Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}